India · Delayed Price · Currency is INR Bacil Pharma Statistics
Total Valuation
Bacil Pharma has a market cap or net worth of INR 615.60 million. The enterprise value is 599.66 million.
| Market Cap | 615.60M |
| Enterprise Value | 599.66M |
Important Dates
The next estimated earnings date is Wednesday, February 11, 2026.
| Earnings Date | Feb 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Bacil Pharma has 14.35 million shares outstanding. The number of shares has increased by 71.68% in one year.
| Current Share Class | 14.35M |
| Shares Outstanding | 14.35M |
| Shares Change (YoY) | +71.68% |
| Shares Change (QoQ) | -0.94% |
| Owned by Insiders (%) | 51.91% |
| Owned by Institutions (%) | n/a |
| Float | 4.77M |
Valuation Ratios
The trailing PE ratio is 69.30.
| PE Ratio | 69.30 |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 2.34 |
| P/TBV Ratio | 2.34 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 94.20 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 13.36
| Current Ratio | 13.36 |
| Quick Ratio | 6.99 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -425.65 |
Financial Efficiency
Return on equity (ROE) is 4.54% and return on invested capital (ROIC) is -0.87%.
| Return on Equity (ROE) | 4.54% |
| Return on Assets (ROA) | -1.23% |
| Return on Invested Capital (ROIC) | -0.87% |
| Return on Capital Employed (ROCE) | -1.07% |
| Weighted Average Cost of Capital (WACC) | 7.48% |
| Revenue Per Employee | n/a |
| Profits Per Employee | 3.18M |
| Employee Count | 2 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Bacil Pharma has paid 2.30 million in taxes.
| Income Tax | 2.30M |
| Effective Tax Rate | 26.50% |
Stock Price Statistics
The stock price has decreased by -0.21% in the last 52 weeks. The beta is 0.59, so Bacil Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.59 |
| 52-Week Price Change | -0.21% |
| 50-Day Moving Average | 38.79 |
| 200-Day Moving Average | 42.18 |
| Relative Strength Index (RSI) | 58.55 |
| Average Volume (20 Days) | 12,168 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -2.81M |
| Pretax Income | 8.66M |
| Net Income | 6.37M |
| EBITDA | -2.81M |
| EBIT | -2.81M |
| Earnings Per Share (EPS) | 0.62 |
Balance Sheet
The company has 15.94 million in cash and n/a in debt, with a net cash position of 15.94 million or 1.11 per share.
| Cash & Cash Equivalents | 15.94M |
| Total Debt | n/a |
| Net Cash | 15.94M |
| Net Cash Per Share | 1.11 |
| Equity (Book Value) | 263.50M |
| Book Value Per Share | 19.09 |
| Working Capital | 29.01M |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Bacil Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -71.68% |
| Shareholder Yield | -71.68% |
| Earnings Yield | 1.03% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |